Compass Therapeutics today announced the first patient has been dosed in its multi-center, open-label, first-in-human Phase 1 trial of CTX-471, a fully human monoclonal antibody that binds and activates a unique epitope of the co-stimulatory [...]
Covetrus (NASDAQ: CVET) was named Healthcare IT Exit of the Year at the 2019 New England Venture Capital Association's NEVY Awards. Other nominees included PillPack, Circulation, and SHYFT Analytics. Read More
Adimab closed out 2018 with 10 new partnerships and six expanded deals. The drug discovery player is continuing that streak with three more deal expansions, with Novartis, Regeneron and Takeda. Read More
For over a decade and a half, the Built Environment Investment Team at Borealis Ventures has been funding and mentoring firms ready to build a better world. As the portfolio and market demand continued to grow, the decision to create a new dedicated venture strategy was a natural one. In 2018, we decided to leverage all of the expertise from the Borealis Ventures Built Environment Investment Team and give it even greater focus by forming Building Ventures, entirely committed to funding disruptive ideas in the built environment for a better built world.
We’re always interested in engaging with inventors, creators, and entrepreneurs to help develop ideas and realize visions.